Exact Mass: 492.2373
Exact Mass Matches: 492.2373
Found 500 metabolites which its exact mass value is equals to given mass value 492.2373
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
rac-5,6-Epoxy-retinoyl-beta-D-glucuronide
This compound belongs to the family of Diterpene Glycosides. These are diterpenes in which an isoprene unit is glycosylated.
4-Hydroxyretinoic acid glucuronide
4-Hydroxyretinoic acid glucuronide belongs to the class of organic compounds known as diterpene glycosides. These are diterpenoids in which an isoprene unit is glycosylated.
2-[4-[2-[(2,4-Difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic acid
Vorapaxar
PA(2:0/18:1(12Z)-O(9S,10R))
PA(2:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(12Z)-O(9S,10R)/2:0)
PA(18:1(12Z)-O(9S,10R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/2:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/18:1(9Z)-O(12,13))
PA(2:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(9Z)-O(12,13)/2:0)
PA(18:1(9Z)-O(12,13)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/2:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
leukotriene-D4
Leukotriene-d4 is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Leukotriene-d4 can be found in a number of food items such as prunus (cherry, plum), horned melon, wasabi, and grass pea, which makes leukotriene-d4 a potential biomarker for the consumption of these food products.
Tepotinib
Taxuspine W
Taxuspine W is a natural product found in Taxus wallichiana, Taxus baccata, and other organisms with data available.
(3E,7E)-2alpha,10beta,13alpha-triacetoxy-5alpha,20-dihydroxy-3,8-secotaxa-3,7,11-trien-9-one|(3E,7E)-2??,10??,13??-Triacetoxy-5??,20-dihydroxy-3,8-seco-taxa-3,7,11-trien-9-one
1alpha,3beta-dihydroxy-7beta,11beta,15beta-triacetoxy-ent-kaur-16-en-6-one|nervonin C
1alpha,3beta-dihydroxy-6alpha,7beta,11beta-triacetoxy-ent-kaur-16-en-15-one|nervonin B
durumolide H|rel-(1R,3S,4S,13R,14R,7E,11E)-3,13,18-triacetoxy-4-hydroxycembra-7,11,15(17)-trien-16,14-olide
3beta-hydroxy-8beta-<5-hydroxy-4-(2-hydroxy-3-methylvaleroyloxy)tigloyloxy>costunolide|3beta-hydroxy-8beta-[5-hydroxy-4-(2-hydroxy-3-methylvaleroyloxy)tigloyloxy]costunolide
Acetic acid 2,3-bis(3,4,5-trimethoxybenzyl)-4-hydroxybutyl ester
2alpha,7beta,13alpha-triacetoxy-5alpha,9alpha-dihydroxy-2(3->20)abeotaxa-4(20),11-dien-10-one|2??,7??,13??-Triacetoxy-5??,9??-dihydroxy-2(3鈥樏傗垎20)abeotaxa-4(20),11-dien-10-one
2alpha,7beta,10beta-triacetoxy-5alpha,13alpha-dihydroxy-2(3->20)abeotaxa-4(20),11-dien-9-one
2alpha,9alpha,10beta-triacetoxy-11,12-epoxy-20-hydroxytaxa-4-en-13-one
(1alpha,11beta,15beta)-1,6,11-triacetyloxy-15-hydroxy-6,7-seco-ent-kaur-16-en-7,20-olide|isorubesin A
(1S,4S,5S,6R,7R,8S,9S,10S)-1,15-diacetoxy-9-benzoyloxy-4,6,8-trihydroxy-dihydro-beta-agarofuran
GW 9578
Ala Phe Gln Gln
Ala Gln Phe Gln
Ala Gln Gln Phe
Cys Asp Lys Lys
Cys Lys Asp Lys
Cys Lys Lys Asp
Cys Lys Arg Ser
Cys Lys Ser Arg
Cys Arg Lys Ser
Cys Arg Ser Lys
Cys Ser Lys Arg
Cys Ser Arg Lys
Asp Cys Lys Lys
Asp Lys Cys Lys
Asp Lys Lys Cys
Glu Ile Met Thr
Glu Ile Thr Met
Glu Leu Met Thr
Glu Leu Thr Met
Glu Met Ile Thr
Glu Met Leu Thr
Glu Met Thr Ile
Glu Met Thr Leu
Glu Thr Ile Met
Glu Thr Leu Met
Glu Thr Met Ile
Glu Thr Met Leu
Phe Ala Gln Gln
Phe Gly Asn Arg
Phe Gly Arg Asn
Phe Met Pro Val
Phe Met Val Pro
Phe Asn Gly Arg
Phe Asn Asn Val
Phe Asn Arg Gly
Phe Asn Val Asn
Phe Pro Met Val
Phe Pro Val Met
Phe Gln Ala Gln
Phe Gln Gln Ala
Phe Arg Gly Asn
Phe Arg Asn Gly
Phe Val Met Pro
Phe Val Asn Asn
Phe Val Pro Met
Gly Phe Asn Arg
Gly Phe Arg Asn
Gly Asn Phe Arg
Gly Asn Arg Phe
Gly Arg Phe Asn
Gly Arg Asn Phe
His His Ile Ser
His His Leu Ser
His His Ser Ile
His His Ser Leu
His His Thr Val
His His Val Thr
His Ile His Ser
His Ile Ser His
His Leu His Ser
His Leu Ser His
His Ser His Ile
His Ser His Leu
His Ser Ile His
His Ser Leu His
His Thr His Val
His Thr Val His
His Val His Thr
His Val Thr His
Ile Glu Met Thr
Ile Glu Thr Met
Ile His His Ser
Ile His Ser His
Ile Met Glu Thr
Ile Met Met Val
Ile Met Thr Glu
Ile Met Val Met
Ile Ser His His
Ile Thr Glu Met
Ile Thr Met Glu
Ile Val Met Met
Lys Cys Asp Lys
Lys Cys Lys Asp
Lys Cys Arg Ser
Lys Cys Ser Arg
Lys Asp Cys Lys
Lys Asp Lys Cys
Lys Lys Cys Asp
Lys Lys Asp Cys
Lys Met Asn Thr
Lys Met Gln Ser
Lys Met Ser Gln
Lys Met Thr Asn
Lys Asn Met Thr
Lys Asn Thr Met
Lys Gln Met Ser
Lys Gln Ser Met
Lys Arg Cys Ser
Lys Arg Ser Cys
Lys Ser Cys Arg
Lys Ser Met Gln
Lys Ser Gln Met
Lys Ser Arg Cys
Lys Thr Met Asn
Lys Thr Asn Met
Leu Glu Met Thr
Leu Glu Thr Met
Leu His His Ser
Leu His Ser His
Leu Met Glu Thr
Leu Met Met Val
Leu Met Thr Glu
Leu Met Val Met
Leu Ser His His
Leu Thr Glu Met
Leu Thr Met Glu
Leu Val Met Met
Met Glu Ile Thr
Met Glu Leu Thr
Met Phe Pro Val
Met Phe Val Pro
Met Ile Met Val
Met Ile Val Met
Met Lys Asn Thr
Met Lys Gln Ser
Met Lys Ser Gln
Met Lys Thr Asn
Met Leu Met Val
Met Leu Val Met
Met Met Ile Val
Met Met Leu Val
Met Met Val Ile
Met Met Val Leu
Met Asn Lys Thr
Met Asn Thr Lys
Met Pro Phe Val
Met Pro Val Phe
Met Gln Lys Ser
Met Gln Ser Lys
Met Ser Lys Gln
Met Ser Gln Lys
Met Thr Lys Asn
Met Thr Leu Glu
Met Thr Asn Lys
Met Val Phe Pro
Met Val Ile Met
Met Val Leu Met
Met Val Met Ile
Met Val Met Leu
Met Val Pro Phe
Asn Phe Gly Arg
Asn Phe Asn Val
Asn Phe Arg Gly
Asn Phe Val Asn
Asn Gly Phe Arg
Asn Gly Arg Phe
Asn Lys Met Thr
Asn Lys Thr Met
Asn Met Lys Thr
Asn Met Thr Lys
Asn Asn Phe Val
Asn Asn Val Phe
Asn Arg Phe Gly
Asn Arg Gly Phe
Asn Thr Lys Met
Asn Thr Met Lys
Asn Val Phe Asn
Asn Val Asn Phe
Pro Phe Met Val
Pro Phe Val Met
Pro Met Phe Val
Pro Met Val Phe
Pro Val Phe Met
Pro Val Met Phe
Gln Ala Phe Gln
Gln Ala Gln Phe
Gln Phe Ala Gln
Gln Phe Gln Ala
Gln Lys Met Ser
Gln Lys Ser Met
Gln Met Lys Ser
Gln Met Ser Lys
Gln Gln Ala Phe
Gln Gln Phe Ala
Gln Ser Lys Met
Gln Ser Met Lys
Arg Cys Lys Ser
Arg Cys Ser Lys
Arg Phe Gly Asn
Arg Phe Asn Gly
Arg Gly Phe Asn
Arg Gly Asn Phe
Arg Lys Cys Ser
Arg Lys Ser Cys
Arg Asn Phe Gly
Arg Asn Gly Phe
Arg Ser Cys Lys
Arg Ser Lys Cys
Ser Cys Lys Arg
Ser Cys Arg Lys
Ser His His Ile
Ser His His Leu
Ser His Ile His
Ser His Leu His
Ser Ile His His
Ser Lys Cys Arg
Ser Lys Met Gln
Ser Lys Gln Met
Ser Lys Arg Cys
Ser Leu His His
Ser Met Lys Gln
Ser Met Gln Lys
Ser Gln Lys Met
Ser Gln Met Lys
Ser Arg Cys Lys
Ser Arg Lys Cys
Thr Glu Ile Met
Thr Glu Leu Met
Thr Glu Met Ile
Thr Glu Met Leu
Thr His His Val
Thr His Val His
Thr Ile Glu Met
Thr Ile Met Glu
Thr Lys Met Asn
Thr Lys Asn Met
Thr Leu Glu Met
Thr Leu Met Glu
Thr Met Glu Ile
Thr Met Glu Leu
Thr Met Ile Glu
Thr Met Lys Asn
Thr Met Leu Glu
Thr Met Asn Lys
Thr Asn Lys Met
Thr Asn Met Lys
Thr Val His His
Val Phe Met Pro
Val Phe Asn Asn
Val Phe Pro Met
Val His His Thr
Val His Thr His
Val Ile Met Met
Val Leu Met Met
Val Met Phe Pro
Val Met Ile Met
Val Met Leu Met
Val Met Met Ile
Val Met Met Leu
Val Met Pro Phe
Val Asn Phe Asn
Val Asn Asn Phe
Val Pro Phe Met
Val Pro Met Phe
Val Thr His His
Vorapaxar
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C78274 - Agent Affecting Cardiovascular System COVID info from Guide to PHARMACOLOGY Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
tepotinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164000 - c-Met-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D000970 - Antineoplastic Agents
2,2-[1,4-Phenylenebis(methyleneimino-4,1-phenyleneoxy)]bis[2-methylpropanoic acid]
ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate
5,6-Epoxyretinoyl glucuronide
D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids
ethyl N-[9-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate
[(2R)-1-acetyloxy-3-phosphonooxypropan-2-yl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
[(2R)-2-acetyloxy-3-phosphonooxypropyl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
3-[1-azepanyl-[1-[(4-fluorophenyl)methyl]-5-tetrazolyl]methyl]-6,7-dimethoxy-1H-quinolin-2-one
(1R,2S,4aS,5R,6S,8R,8aS)-8a-[(acetyloxy)methyl]-5,6-dimethyl-5-[(2R,3aR,6aR)-2,3,3a,6a-tetrahydrofuro[2,3-b]furan-2-yl]octahydro-2H-spiro[naphthalene-1,2-oxirane]-2,8-diyl diacetate
3-[(1-tert-butyl-5-tetrazolyl)-[2-furanylmethyl(2-oxolanylmethyl)amino]methyl]-6-methoxy-1H-quinolin-2-one
(2S,3S,3aR,9bR)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(2R,3R,3aS,9bS)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(1S)-1-(hydroxymethyl)-7-methoxy-1-[oxo(2-pyrazinyl)methyl]-N-propan-2-yl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
1-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-[oxo(2-pyridinyl)methyl]-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-2-methoxyethanone
(1R)-1-(hydroxymethyl)-7-methoxy-1-[oxo(2-pyrazinyl)methyl]-N-propan-2-yl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
1-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-[oxo(2-pyridinyl)methyl]-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-2-methoxyethanone
4-(beta-D-glucopyranuronosyloxy)retinoic acid
A hydroxyretinoic glucuronide that is all-trans-4-hydroxyretinoic acid attached to a beta-D-glucuronic acid residue via a glycosidic linkage.
1-O-all-trans-4-hydroxyretinoyl-beta-glucuronic acid
A hydroxyretinoic glucuronide obtained by the glycosylation of the carboxy group of all-trans-4-hydroxyretinoic acid with beta-glucuronic acid.
(2R,3R,3aS,9bS)-1-N-cyclopentyl-3-(hydroxymethyl)-6-oxo-7-[(E)-prop-1-enyl]-2-N-(pyrimidin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
methyl 6-{[4-deoxy-4-formamido-alpha-D-rhamnopyranosyl-(1->3)-4-deoxy-4-formamido-alpha-D-rhamnopyranosyl]oxy}hexanoate
(2S,3S,3aR,9bR)-1-N-cyclopentyl-3-(hydroxymethyl)-6-oxo-7-[(E)-prop-1-enyl]-2-N-(pyrimidin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
1-O-(5,6-epoxyretinoyl)-beta-D-glucuronic acid
A retinoid that is 5,6-epoxyretinoic acid in which the carboxy proton has been replaced by a beta-D-glucuronyl residue.
3,12-bis(acetyloxy)-10,14-dihydroxy-7,11,16,16-tetramethyl-9-oxotricyclo[9.3.1.1⁴,⁸]hexadeca-1,7-dien-6-yl acetate
(1r,2s)-1-[(1r,4as,8s,9r,11ar)-1-(acetyloxy)-8,9-dihydroxy-7-methyl-11-methylidene-1h,4ah,5h,8h,9h,10h,11ah-cyclonona[c]pyran-4-yl]-1-(acetyloxy)-4-methylpent-3-en-2-yl acetate
4,8,11b-trimethyl-4-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-1h,2h,3h,4ah,5h,6h,10ah,11h-phenanthro[3,2-b]furan-7,9-dione
(1s,2r,3s,4r,7s,8z,12r,13s,14s)-12,14-bis(acetyloxy)-3-hydroxy-4,9,13,17-tetramethyl-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadeca-8,16-dien-2-yl acetate
(1r,2s,4ar,5r,6s,7r,8r,8ar)-2,7-bis(acetyloxy)-5-[2-(furan-3-yl)ethyl]-8-hydroxy-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-8a-ylmethyl acetate
(2r,3s)-4-hydroxy-2,3-bis[(3,4,5-trimethoxyphenyl)methyl]butyl acetate
(1s,2r,3s,4r,7s,8z,12r,13s,14s)-12,14-bis(acetyloxy)-3-hydroxy-4,9,13-trimethyl-17-methylidene-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadec-8-en-2-yl acetate
2,11-bis(acetyloxy)-6,8-dihydroxy-5,5,9-trimethyl-14-methylidene-3-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-15-yl acetate
(1e,3s,4r,6s,9r,11s,12s,14s)-3,12-bis(acetyloxy)-9,14-dihydroxy-7,11,16,16-tetramethyl-10-oxotricyclo[9.3.1.1⁴,⁸]hexadeca-1,7-dien-6-yl acetate
(4r,4as,10ar,11br)-4,8,11b-trimethyl-4-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-1h,2h,3h,4ah,5h,6h,10ah,11h-phenanthro[3,2-b]furan-7,9-dione
5-(3-chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-3-methyl-1-(1,2,6-trimethyl-3-oxocyclohexyl)pent-3-en-2-yl butanoate
(1r,2r,3r,4s,6r,7s,9s,10s,11s,13s)-6,7-bis(acetyloxy)-3,11-dihydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-2-yl acetate
(1r,2r,3r,4s,6r,7s,9s,10s,11s,13s)-2,6-bis(acetyloxy)-3,7-dihydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-yl acetate
(1r,2s,3e,5s,7e,10r,13s)-2,10-bis(acetyloxy)-5-hydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-9-oxobicyclo[9.3.1]pentadeca-3,7,11-trien-13-yl acetate
(1'r,2s,2'r,3'r,5's,8'r,9'r,10'r)-9',10'-bis(acetyloxy)-5'-hydroxy-8',12',15',15'-tetramethyl-13'-oxospiro[oxirane-2,4'-tricyclo[9.3.1.0³,⁸]pentadecan]-11'-en-2'-yl acetate
(1r,2s,3r,4r,7s,9r,10r,11r,14s)-2,3-bis(acetyloxy)-7-hydroxy-4,14,16,16-tetramethyl-8-methylidene-13-oxo-15-oxatetracyclo[9.4.1.0¹,¹⁴.0⁴,⁹]hexadecan-10-yl acetate
2,8-bis(acetyloxy)-6,15-dihydroxy-5,5,9-trimethyl-14-methylidene-3-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-yl acetate
(1r,2s,3r,5s,7r,8s,9s,10s,11r,15s)-3,15-bis(acetyloxy)-9,10-dihydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-7-yl acetate
2,7-bis(acetyloxy)-6,11-dihydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-3-yl acetate
(2r,4s,5s,7s,8e,10s,11r,13s)-2,10-bis(acetyloxy)-7,13-dihydroxy-4,14,15,15-tetramethyl-3-oxotricyclo[9.3.1.1⁴,⁸]hexadeca-1(14),8-dien-5-yl acetate
14-deoxo-14-O- acetylorthosiphol Y
{"Ingredient_id": "HBIN001404","Ingredient_name": "14-deoxo-14-O- acetylorthosiphol Y","Alias": "14-deoxo-14-o-acetylorthosiphol y","Ingredient_formula": "C26H36O9","Ingredient_Smile": "CC(=O)OC1CC2C(C(=O)C(=CC2(C3C1(C(C(CC3O)(C)C=C)OC(=O)C)O)C)OC(=O)C)(C)C","Ingredient_weight": "492.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "37493;5136","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "21578028","DrugBank_id": "NA"}
1-hydroxytaxinine a
{"Ingredient_id": "HBIN002663","Ingredient_name": "1-hydroxytaxinine a","Alias": "NA","Ingredient_formula": "C26H36O9","Ingredient_Smile": "CC1=C2C(C(C3(CCC(C(=C)C3C(C(C2(C)C)(CC1=O)O)OC(=O)C)O)C)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15918","TCMID_id": "10738","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2α,7β,13α-triacetoxy-5α,9α-dihydroxy-2(3→20)abeotaxa-4(20),11-dien-10-one
{"Ingredient_id": "HBIN005252","Ingredient_name": "2\u03b1,7\u03b2,13\u03b1-triacetoxy-5\u03b1,9\u03b1-dihydroxy-2(3\u219220)abeotaxa-4(20),11-dien-10-one","Alias": "NA","Ingredient_formula": "C26H36O9","Ingredient_Smile": "CC(=O)OC1CC2CC3(C1C4(C(CC(C(C4C(=O)C3O)(C)C)O)OC(=O)C)C)C(C2=C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21499","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-deacetyltaxine b
{"Ingredient_id": "HBIN005509","Ingredient_name": "2-deacetyltaxine b","Alias": "NA","Ingredient_formula": "C26H36O9","Ingredient_Smile": "CC1=C2C(C(=O)C3(CC(=CC(C(C2(C)C)CC1OC(=O)C)O)C(CC3OC(=O)C)O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4780","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-deactyltaxine b
{"Ingredient_id": "HBIN005510","Ingredient_name": "2-deactyltaxine b","Alias": "NA","Ingredient_formula": "C26H36O9","Ingredient_Smile": "CC1=C2C(C(=O)C3(CC(=CC(C(C2(C)C)CC1OC(=O)C)O)C(CC3OC(=O)C)O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "30479","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(3 e,7 e)-2α,10β,13α-triacetoxy-5α,20-dihydrox-y-3,8-seco-taxa-3,7,11-trien-9-one
{"Ingredient_id": "HBIN008454","Ingredient_name": "(3 e,7 e)-2\u03b1,10\u03b2,13\u03b1-triacetoxy-5\u03b1,20-dihydrox-y-3,8-seco-taxa-3,7,11-trien-9-one","Alias": "NA","Ingredient_formula": "C26H36O9","Ingredient_Smile": "CC(=O)OC1CC2CC3(C1C4(C(CC(C(C4C(=O)C3O)(C)C)O)OC(=O)C)C)C(C2=C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21500","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(3E,7E)-2alpha,10beta,13alpha-Triacetoxy-5alpha,20-dihydroxy-3,8-seco-taxa-3,7,11-trien-9-one
{"Ingredient_id": "HBIN008455","Ingredient_name": "(3E,7E)-2alpha,10beta,13alpha-Triacetoxy-5alpha,20-dihydroxy-3,8-seco-taxa-3,7,11-trien-9-one","Alias": "[(1R,2S,3E,5S,7E,10R,13S)-2,10-diacetyloxy-5-hydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-9-oxo-13-bicyclo[9.3.1]pentadeca-3,7,11-trienyl] acetate; acetic acid [(1R,2S,3E,5S,7E,10R,13S)-2,10-diacetoxy-5-hydroxy-9-keto-8,12,15,15-tetramethyl-4-methylol-13-bicyclo[9.3.1]pentadeca-3,7,11-trienyl] ester; (3e,7e)-2alpha,10beta,13alpha-triacetoxy-5alpha,20-dihydroxy-3,8-seco-taxa-3,7,11-trien-9-one; [(1R,2S,3E,5S,7E,10R,13S)-2,10-diacetoxy-5-hydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-9-oxo-13-bicyclo[9.3.1]pentadeca-3,7,11-trienyl] acetate; acetic acid [(1R,2S,3E,5S,7E,10R,13S)-2,10-diacetoxy-5-hydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-9-oxo-13-bicyclo[9.3.1]pentadeca-3,7,11-trienyl] ester; [(1R,2S,3E,5S,7E,10R,13S)-2,10-diacetyloxy-5-hydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-9-oxo-13-bicyclo[9.3.1]pentadeca-3,7,11-trienyl] ethanoate","Ingredient_formula": "C26H36O9","Ingredient_Smile": "CC1=CCC(C(=CC(C2CC(C(=C(C2(C)C)C(C1=O)OC(=O)C)C)OC(=O)C)OC(=O)C)CO)O","Ingredient_weight": "492.6 g/mol","OB_score": "7.933338771","CAS_id": "NA","SymMap_id": "SMIT01016","TCMID_id": "32087","TCMSP_id": "MOL003237","TCM_ID_id": "NA","PubChem_id": "6326196","DrugBank_id": "NA"}
adenanthin j
{"Ingredient_id": "HBIN014681","Ingredient_name": "adenanthin j","Alias": "NA","Ingredient_formula": "C26H36O9","Ingredient_Smile": "CC(=O)OC1CC2CC3(C1C4(C(CC(C(C4C(=O)C3OC(=O)C)(C)C)O)OC(=O)C)C)C(C2=C)O","Ingredient_weight": "492.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "614","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "11081505","DrugBank_id": "NA"}
adenanthin k
{"Ingredient_id": "HBIN014682","Ingredient_name": "adenanthin k","Alias": "NA","Ingredient_formula": "C26H36O9","Ingredient_Smile": "CC(=O)OC1CC2CC3(C1C4(C(CC(C(C4C(=O)C3O)(C)C)O)OC(=O)C)C)C(C2=C)OC(=O)C","Ingredient_weight": "492.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "615","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "11081506","DrugBank_id": "NA"}